<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01428024</url>
  </required_header>
  <id_info>
    <org_study_id>31GE1102</org_study_id>
    <nct_id>NCT01428024</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy, Safety and Injection Technique of Restylane Lip Volume and Restylane Lip Refresh</brief_title>
  <official_title>An Open, Multi-center Study Evaluating Efficacy, Safety and Injection Technique of Restylane Lip Products for Lip Enhancement and Lip Rejuvenation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the efficacy and safety of two new Restylane Lip
      products, Restylane Lip Volume and Restylane Lip Refresh, and to collect information on the
      injection technique.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Restylane Lip Volume is intended to be used for lip enhancement and Restylane Lip Refresh is
      intended to restore hydrobalance and improve skin structure of the lips (referred to as lip
      rejuvenation in this protocol), respectively. The lidocaine content is designed to reduce the
      subject's pain during treatment. The objectives of this open, multicenter study are to
      evaluate efficacy and safety of the products for the studied indications and to collect
      information on injection techniques used.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GEIS (Global Esthetic Improvement Scale) Assessed by the Subject at Week 8 After Treatment</measure>
    <time_frame>At week 8 - change of lips from baseline</time_frame>
    <description>To evaluate esthetic change of lips from baseline as judged by the subjects using GEIS. GEIS is a categorical scale with five levels: very much improved, much improved, somewhat improved, no change, worse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GEIS (Global Esthetic Improvement Scale) Assessed by the Subject at Week 36 After Treatment</measure>
    <time_frame>week 36 - change from baseline</time_frame>
    <description>To evaluate esthetic change of lips from baseline as judged by the subjects using GEIS at week 36. GEIS is a categorical scale with five levels: very much improved, much improved, somewhat improved, no change, worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GEIS (Global Esthetic Improvement Scale) Assessed by the Treating Investigator at Week 36 After Treatment</measure>
    <time_frame>week 36 - change from baseline</time_frame>
    <description>To evaluate esthetic change of lips from baseline as judged by the treating investigator using GEIS at week 36. GEIS is a categorical scale with five levels: very much improved, much improved, somewhat improved, no change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GEIS (Global Esthetic Improvement Scale) Assessed by the Independent Evaluator at Week 36 After Treatment</measure>
    <time_frame>week 36 - change from baseline</time_frame>
    <description>To evaluate esthetic change of lips from baseline as judged by the independent evaluator using GEIS at week 2, 4, 12, 26 and 36. GEIS is a categorical scale with five levels: very much improved, much improved, somewhat improved, no change, worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MLFS (Medicis Lip Fullness Scale) at Week 8</measure>
    <time_frame>week 8 - change from baseline</time_frame>
    <description>To evaluate the efficacy in terms of Medicis Lip Fullness Scale (MLFS) score by live assessment performed separately by the treating and the independent investigators in the Restylane Lip Volume group. The scale has five levels: Very thin, thin, median, full, very full. Treatment success is defined as at least one grade increase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction Questionnaire</measure>
    <time_frame>Week 8</time_frame>
    <description>To evaluate subjects satisfaction in terms of a subject satisfaction questionnaire at week 8 after treatment.
The subject satisfaction questionnaire consists of questions regarding the looks, appearance, disomfort, and satisfaction regarding the treatment of the lips.
The question that will be referred to is: How satisfied are you today with (the look of) your lips ?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Diary for 14 Days After Initial Treatment</measure>
    <time_frame>2 weeks after initial treatment</time_frame>
    <description>To evaluate the acute safety profile (bruising, itching, pain, redness, swelling and tenderness) in terms of a 14-day subject diary after initial treatment.
Subjects still reporting one or more of the symptoms; bruising, itching, pain, redness, swelling and tenderness in the diary at day 14.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Injection Techniques</condition>
  <arm_group>
    <arm_group_label>Restylane Lip Volume</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Submucosal injections with Restylane Lip Volume. Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 2 and 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restylane Lip Refresh</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Submucosal injections with Restylane Lip Refresh. Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 2 and 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane Lip Volume</intervention_name>
    <description>Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.</description>
    <arm_group_label>Restylane Lip Volume</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane Lip Refresh</intervention_name>
    <description>Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.</description>
    <arm_group_label>Restylane Lip Refresh</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 60 years of age.

          -  Intent to undergo lip augmentation or rejuvenation of both the upper and lower lip.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Prior surgery or tattoo to the upper or lower lip or lip line.

          -  Presence of any abnormal lip structure, such as a scar or lump or severe lip
             asymmetry.

          -  A history of herpes labialis and an outbreak within four weeks of study entry or with
             four or more outbreaks in the 12 months prior to study entry.

          -  Presence of facial hair that may interfere with efficacy evaluations.

          -  Active skin disease, inflammation or related conditions, such as infection, psoriasis
             and herpes zoster near or on the area to be treated.

          -  History of angioedema.

          -  Previous hypersensitivity to hyaluronic acid or local anesthetics.

          -  Concomitant anticoagulant therapy and therapy with inhibitors of platelet aggregation
             within 10 days prior to treatment, or a history of bleeding disorders.

          -  Cancerous or pre-cancerous lesions in the area to be treated.

          -  Previous tissue augmenting therapy in the area to be treated with hyaluronic acid (HA)
             or collagen filler, or laser treatment, during the last 12 months.

          -  Permanent implant placed in the area to be treated or treatment with non-HA or
             non-collagen filler in the area to be treated.

          -  Pregnancy or breast feeding.

          -  Participation in any other clinical study within 30 days prior to inclusion.

          -  Other condition preventing the subject to entering the study in the Investigator's
             opinion e.g. subjects not likely to avoid other facial cosmetic treatments below the
             level of the lower orbital rim, subjects anticipated to be unreliable or incapable of
             understanding the study assessment or unrealistic expectations of treatment result.

          -  Study staff or close relative to study staff (e.g. parents, children, siblings or
             spouse).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulf Samuelsson, Med Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Akademikliniken, Storängsvägen 10, 115 42 Stockholm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan Fagrell, Med Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Göteborgs Plastikirurgiska Center, Fridkullagatan 35 412 65 Göteborg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pyra Haglund, Med Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stureplanskliniken, Lästmakargatan 10, 111 44 Stockholm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Göteborgs Plastikkirurgiska Center</name>
      <address>
        <city>Göteborg</city>
        <zip>412 65</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stureplanskliniken</name>
      <address>
        <city>Stockholm</city>
        <zip>111 44</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademikliniken</name>
      <address>
        <city>Stockholm</city>
        <zip>115 42</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>August 31, 2011</study_first_submitted>
  <study_first_submitted_qc>September 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2011</study_first_posted>
  <results_first_submitted>November 29, 2013</results_first_submitted>
  <results_first_submitted_qc>October 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 18, 2018</results_first_posted>
  <last_update_submitted>October 17, 2018</last_update_submitted>
  <last_update_submitted_qc>October 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>Restylane</keyword>
  <keyword>Lip products</keyword>
  <keyword>injection techniques</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Restylane LipVolume</title>
          <description>Open label
Restylane Lip Volume : Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.</description>
        </group>
        <group group_id="P2">
          <title>Restylane Lip Refresh</title>
          <description>Open label
Restylane Lip Refresh : Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Restylane LipVolume</title>
          <description>Open label
Restylane Lip Volume : Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and week 12.</description>
        </group>
        <group group_id="B2">
          <title>Restylane Lip Refresh</title>
          <description>Open label
Restylane Lip Refresh : Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and week 12.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.1" spread="12.5"/>
                    <measurement group_id="B2" value="49.4" spread="6.4"/>
                    <measurement group_id="B3" value="42.8" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>GEIS (Global Esthetic Improvement Scale) Assessed by the Subject at Week 8 After Treatment</title>
        <description>To evaluate esthetic change of lips from baseline as judged by the subjects using GEIS. GEIS is a categorical scale with five levels: very much improved, much improved, somewhat improved, no change, worse.</description>
        <time_frame>At week 8 - change of lips from baseline</time_frame>
        <population>One subject did not perform GEIS evaluation at the 8-week visit and withdrew consent after the visit</population>
        <group_list>
          <group group_id="O1">
            <title>Restylane Lip Volume</title>
            <description>GEIS (Global Esthetic Improvement Scale)subject at 8 weeks (change from baseline).
Injection with Restylane Lip Volume (a Hyaluronic acid gel)with maximum 1.5 ml for each upper/lower lip.</description>
          </group>
          <group group_id="O2">
            <title>Restylane Lip Refresh</title>
            <description>GEIS (Global Esthetic Improvement Scale)subject at 8 weeks (change from baseline).
Injection with Restylane Lip Refresh (a Hyaluronic acid gel)with maximum 0.5 ml for each upper/lower lip.</description>
          </group>
        </group_list>
        <measure>
          <title>GEIS (Global Esthetic Improvement Scale) Assessed by the Subject at Week 8 After Treatment</title>
          <description>To evaluate esthetic change of lips from baseline as judged by the subjects using GEIS. GEIS is a categorical scale with five levels: very much improved, much improved, somewhat improved, no change, worse.</description>
          <population>One subject did not perform GEIS evaluation at the 8-week visit and withdrew consent after the visit</population>
          <units>percentage improved subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" lower_limit="68.3" upper_limit="96.1"/>
                    <measurement group_id="O2" value="86.7" lower_limit="69.3" upper_limit="96.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GEIS (Global Esthetic Improvement Scale) Assessed by the Subject at Week 36 After Treatment</title>
        <description>To evaluate esthetic change of lips from baseline as judged by the subjects using GEIS at week 36. GEIS is a categorical scale with five levels: very much improved, much improved, somewhat improved, no change, worse.</description>
        <time_frame>week 36 - change from baseline</time_frame>
        <population>Restylane Lip Volume: One subject withdrew consent after the 8-week visit and thus did not perform the GEIS evaluation at 36 weeks.
Restylane Lip Refresh: Two subjects did not perform the GEIS evaluation at 36 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Restylane Lip Volume</title>
            <description>GEIS (Global Esthetic Improvement Scale) subject at 36 weeks (change from baseline).
Injection with Restylane Lip Volume (a Hyaluronic acid gel) with maximum 1.5 ml for each upper/lower lip.</description>
          </group>
          <group group_id="O2">
            <title>Restylane Lip Refresh</title>
            <description>GEIS (Global Esthetic Improvement Scale) subject at 36 weeks (change from baseline).
Injection with Restylane Lip Refresh (a Hyaluronic acid gel) with maximum 0.5 ml for each upper/lower lip.</description>
          </group>
        </group_list>
        <measure>
          <title>GEIS (Global Esthetic Improvement Scale) Assessed by the Subject at Week 36 After Treatment</title>
          <description>To evaluate esthetic change of lips from baseline as judged by the subjects using GEIS at week 36. GEIS is a categorical scale with five levels: very much improved, much improved, somewhat improved, no change, worse.</description>
          <population>Restylane Lip Volume: One subject withdrew consent after the 8-week visit and thus did not perform the GEIS evaluation at 36 weeks.
Restylane Lip Refresh: Two subjects did not perform the GEIS evaluation at 36 weeks.</population>
          <units>percentage improved subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1" lower_limit="77.2" upper_limit="99.2"/>
                    <measurement group_id="O2" value="78.6" lower_limit="59.0" upper_limit="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GEIS (Global Esthetic Improvement Scale) Assessed by the Treating Investigator at Week 36 After Treatment</title>
        <description>To evaluate esthetic change of lips from baseline as judged by the treating investigator using GEIS at week 36. GEIS is a categorical scale with five levels: very much improved, much improved, somewhat improved, no change.</description>
        <time_frame>week 36 - change from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Restylane LipVolume</title>
            <description>GEIS (Global Esthetic Improvement Scale)by treating investigator at 36 weeks (change from baseline).
Injection with Restylane Lip Volume (a Hyaluronic acid gel)with maximum 1.5 ml for each upper/lower lip.</description>
          </group>
          <group group_id="O2">
            <title>Restylane Lip Refresh</title>
            <description>GEIS (Global Esthetic Improvement Scale)by treating investigator at 36 weeks (change from baseline).
Injection with Restylane Lip Refresh (a Hyaluronic acid gel)with maximum 0.5 ml for each upper/lower lip.</description>
          </group>
        </group_list>
        <measure>
          <title>GEIS (Global Esthetic Improvement Scale) Assessed by the Treating Investigator at Week 36 After Treatment</title>
          <description>To evaluate esthetic change of lips from baseline as judged by the treating investigator using GEIS at week 36. GEIS is a categorical scale with five levels: very much improved, much improved, somewhat improved, no change.</description>
          <units>percentage improved subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8" lower_limit="64.2" upper_limit="94.2"/>
                    <measurement group_id="O2" value="82.8" lower_limit="64.2" upper_limit="94.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GEIS (Global Esthetic Improvement Scale) Assessed by the Independent Evaluator at Week 36 After Treatment</title>
        <description>To evaluate esthetic change of lips from baseline as judged by the independent evaluator using GEIS at week 2, 4, 12, 26 and 36. GEIS is a categorical scale with five levels: very much improved, much improved, somewhat improved, no change, worse.</description>
        <time_frame>week 36 - change from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Restylane LipVolume</title>
            <description>GEIS (Global Esthetic Improvement Scale)independent evaluator at 36 weeks (change from baseline).
Injection with Restylane Lip Volume (a Hyaluronic acid gel)with maximum 1.5 ml for each upper/lower lip.</description>
          </group>
          <group group_id="O2">
            <title>Restylane Lip Refresh</title>
            <description>GEIS (Global Esthetic Improvement Scale)independent evaluator at 36 weeks (change from baseline).
Injection with Restylane Lip Refresh (a Hyaluronic acid gel)with maximum 0.5 ml for each upper/lower lip.</description>
          </group>
        </group_list>
        <measure>
          <title>GEIS (Global Esthetic Improvement Scale) Assessed by the Independent Evaluator at Week 36 After Treatment</title>
          <description>To evaluate esthetic change of lips from baseline as judged by the independent evaluator using GEIS at week 2, 4, 12, 26 and 36. GEIS is a categorical scale with five levels: very much improved, much improved, somewhat improved, no change, worse.</description>
          <units>percentage improved subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" lower_limit="68.3" upper_limit="96.1"/>
                    <measurement group_id="O2" value="86.2" lower_limit="68.3" upper_limit="96.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MLFS (Medicis Lip Fullness Scale) at Week 8</title>
        <description>To evaluate the efficacy in terms of Medicis Lip Fullness Scale (MLFS) score by live assessment performed separately by the treating and the independent investigators in the Restylane Lip Volume group. The scale has five levels: Very thin, thin, median, full, very full. Treatment success is defined as at least one grade increase.</description>
        <time_frame>week 8 - change from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Restylane LipVolume</title>
            <description>MLFS (Medicis Lip Fullness Scale)score by live assessment performed separately by the treating and the independent investigators at 8 weeks (change from baseline).
Injection with Restylane Lip Volume (a Hyaluronic acid gel)with maximum 1.5 ml for each upper/lower lip.</description>
          </group>
        </group_list>
        <measure>
          <title>MLFS (Medicis Lip Fullness Scale) at Week 8</title>
          <description>To evaluate the efficacy in terms of Medicis Lip Fullness Scale (MLFS) score by live assessment performed separately by the treating and the independent investigators in the Restylane Lip Volume group. The scale has five levels: Very thin, thin, median, full, very full. Treatment success is defined as at least one grade increase.</description>
          <units>percentage improved subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="31.3" upper_limit="68.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Satisfaction Questionnaire</title>
        <description>To evaluate subjects satisfaction in terms of a subject satisfaction questionnaire at week 8 after treatment.
The subject satisfaction questionnaire consists of questions regarding the looks, appearance, disomfort, and satisfaction regarding the treatment of the lips.
The question that will be referred to is: How satisfied are you today with (the look of) your lips ?</description>
        <time_frame>Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Restylane LipVolume</title>
            <description>Subject satisfaction questionnaire at 8 weeks. Injection of Restylane Lip Volume (a Hyaluronic acid gel) maximum dosage of 1.5 ml per upper/lower lip.</description>
          </group>
          <group group_id="O2">
            <title>Restylane Lip Refresh</title>
            <description>Subject satisfaction questionnaire at 8 weeks. Injection of Restylane Lip Refresh (a Hyaluronic acid gel) maximum dosage of 0.5 ml per upper/lower lip.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Satisfaction Questionnaire</title>
          <description>To evaluate subjects satisfaction in terms of a subject satisfaction questionnaire at week 8 after treatment.
The subject satisfaction questionnaire consists of questions regarding the looks, appearance, disomfort, and satisfaction regarding the treatment of the lips.
The question that will be referred to is: How satisfied are you today with (the look of) your lips ?</description>
          <units>percentage satisfied subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Diary for 14 Days After Initial Treatment</title>
        <description>To evaluate the acute safety profile (bruising, itching, pain, redness, swelling and tenderness) in terms of a 14-day subject diary after initial treatment.
Subjects still reporting one or more of the symptoms; bruising, itching, pain, redness, swelling and tenderness in the diary at day 14.</description>
        <time_frame>2 weeks after initial treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Restylane Lip Volume</title>
            <description>Open label
Restylane Lip Volume : Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.</description>
          </group>
          <group group_id="O2">
            <title>Restylane Lip Refresh</title>
            <description>Open label
Restylane Lip Refresh : Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Diary for 14 Days After Initial Treatment</title>
          <description>To evaluate the acute safety profile (bruising, itching, pain, redness, swelling and tenderness) in terms of a 14-day subject diary after initial treatment.
Subjects still reporting one or more of the symptoms; bruising, itching, pain, redness, swelling and tenderness in the diary at day 14.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Restylane LipVolume</title>
          <description>Open label
Restylane Lip Volume : Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.</description>
        </group>
        <group group_id="E2">
          <title>Restylane Lip Refresh</title>
          <description>Open label
Restylane Lip Refresh : Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral encephalitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Knee joint injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Worsening of benign neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lip dry</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Implant site haematoma</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Implant site mass</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Implant site pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Implant site swelling</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Implant site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Implant site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>oral herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blood blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Medical Affairs</name_or_title>
      <organization>Q-Med AB</organization>
      <phone>+ 46 (0) 18 4749000</phone>
      <email>reception.SEUPP@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

